Physician profile
Ari Fishman
NPI 1407963036
$911.69
in general payments reported to CMS, 2019-2025
19 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.64 · 2020: $14.62 · 2021: $11.92 · 2022: $23.99 · 2023: $267 · 2024: $297 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intera Oncology, INC | $114.21 | 2024 | Intera |
| Pfizer INC. | $98.63 | 2024-2025 | |
| Tempus Ai, INC | $92.18 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $84.53 | 2023-2025 | Keytruda, Keytruda Qlex |
| Glaxosmithkline, LLC. | $77.99 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $77.04 | 2024 | Opdivo |
| Celgene Corporation | $65.18 | 2023 | Opdualag |
| Daiichi Sankyo INC. | $55.12 | 2023 | Enhertu, Injectafer |
| Tersera Therapeutics LLC | $36.71 | 2023 | Xermelo |
| Sumitomo Pharma America, INC. | $28.30 | 2023 | Orgovyx |
| Incyte Corporation | $24.80 | 2023 | Monjuvi, Pemazyre, Jakafi |
| Genentech USA, INC. | $24.64 | 2019 | |
| Grifols USA, LLC | $23.99 | 2022 | |
| Genzyme Corporation | $22.37 | 2025 | |
| Array Biopharma INC | $22.25 | 2025 | Lorbrena, Braftovi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.06 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.41 | 2024 | Calquence |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.